Letter to the Editor
Early clinical experience with imatinib in COVID-19: Searching for a dual effectAuthor links open overlay panel,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
Highlights
- •
Imatinib has shown antiviral and immunomodulatory properties in preclinical models.
- •
Imatinib could potentially be helpful in COVID-19.
- •
This is the first case series of COVID-19 patients treated with imatinib.
- •
Imatinib is a well-known drug whose safety profile seems acceptable in COVID-19.
View Abstract© 2021 The British Infection Association. Published by Elsevier Ltd. All rights reserved.